SCHEMBL5241187

SCHEMBL5241187

C1CC(C2CCNC2)CCN1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 1/20 0.41
GNAI3 P08754 4/20 0.33
GNAO1 P09471 4/20 0.33
GNAI1 P63096 4/20 0.33
GABRA5 P31644 4/20 0.33
GABRB2 P47870 3/20 0.33
GABRA1 P14867 3/20 0.33
GABRA4 P48169 2/20 0.33
TSHR P16473 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 2/20 0.33
GABRA6 Q16445 2/20 0.33
KCNH2 Q12809 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRE P78334 1/20 0.33
PMP22 Q01453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25565963 1.00 CCR5 (0.41) CCR5GNAI3GNAO1GNAI1GABRA5
SCHEMBL14708956 0.93
SCHEMBL27269519 0.93
SCHEMBL1830086 0.93
SCHEMBL17006846 0.93
SCHEMBL17538544 0.93
SCHEMBL1243243 0.93 CCR5 (0.47) CCR5GABRA5GABRB2GABRA1GABRA4
SCHEMBL8007981 0.93 CCR5 (0.47) CCR5GABRA5GABRB2GABRA1GABRA4
SCHEMBL13250365 0.93 CCR5 (0.47) CCR5GABRA5GABRB2GABRA1GABRA4
Hydrochloric Acid SCHEMBL28585458 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515897-B1 PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE H LUNDBECK AS (DK) 2021-08-18 EP disclosed
WO-2018121678-A1 PRODRUG OF ANTIVIRAL NUCLEOSIDE ANALOGUES, AND COMPOSITION AND USE THEREOF 广东东阳光药业有限公司 2018-07-05 WO disclosed
US-7229996-B2 Rifamycin derivatives CUMBRE PHARMACEUTICALS INC. (US) 2007-06-12 US disclosed
US-7229996-B2 Rifamycin derivatives CUMBRE PHARMACEUTICALS INC. (US) 2007-06-12 US disclosed
US-7229996-B2 Rifamycin derivatives CUMBRE PHARMACEUTICALS INC. (US) 2007-06-12 US disclosed
EP-1781670-A1 RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS Cumbre Pharmaceuticals Inc. (US) 2007-05-09 EP disclosed
WO-2006012470-A1 RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS CUMBRE PHARMACEUTICALS INC. (US) 2006-02-02 WO disclosed
US-20060019985-A1 Rifamycin derivatives CUMBRE INC. (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019985-A1 Rifamycin derivatives RIF1, NQO1, MRM1 CCR5 2563/4885GNAI3 3062/4885GNAO1 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.